Enzalutamide + Exemestane
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Breast Cancer ER+ve
Conditions
Primary Breast Cancer ER+ve, Primary Breast Cancer AR+ve TNBN
Trial Timeline
Aug 10, 2015 → Dec 31, 2016
NCT ID
NCT02676986About Enzalutamide + Exemestane
Enzalutamide + Exemestane is a phase 2 stage product being developed by Astellas Pharma for Primary Breast Cancer ER+ve. The current trial status is completed. This product is registered under clinical trial identifier NCT02676986. Target conditions include Primary Breast Cancer ER+ve, Primary Breast Cancer AR+ve TNBN.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02676986 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Breast Cancer ER+ve